ERBB2 and non-small cell lung carcinoma: The 2024 ESMO Congress reported a retrospective analysis of T-DXd retreatment, with data from nine clinical trials covering patients with HER-2-altered breast, gastric, colorectal, and non-small-cell lung cancers who had received at least one dose of T-DXd.